亚洲最大无码中文字幕网站,国产清纯在线一区二区WWW,很黄很黄让你高潮视频,婷婷六月激情综合一区

beat365在線體育官網(wǎng)

College of Biological Science and Engineering

蔡志雄*

發(fā)布日期:2013-06-26 發(fā)布者:

姓名:蔡志雄

性別:

職務(wù)副研究員/碩士生導(dǎo)師

學(xué)歷:博士

電子郵件: caizhixiong1985@163.com

主要研究方向:基于循環(huán)腫瘤DNA的液體活檢,基于腫瘤新抗原的精準(zhǔn)免疫治療。

教育工作經(jīng)歷:

1. 2004-09 至 2008-07, 福建農(nóng)林大學(xué), 生物科學(xué)(微生物方向), 學(xué)士

2.2008-09 至 2011-07, 福建師范大學(xué), 生物化學(xué)與分子生物學(xué), 碩士

3.2016-09 至 2020-03, 西安交通大學(xué), 生物學(xué), 博士

4.2011-09 至 2013-02, 中國科學(xué)院物質(zhì)結(jié)構(gòu)研究所, 吳允昆課題組, 研究實(shí)習(xí)員

5.2013-03 至 2016-09, 福建醫(yī)科大學(xué), 孟超肝膽醫(yī)院, 研究實(shí)習(xí)員

6.2016-09 至 2021-11, 福建醫(yī)科大學(xué), 孟超肝膽醫(yī)院, 助理研究員

7.2021-11至今, 福建醫(yī)科大學(xué), 孟超肝膽醫(yī)院, 副研究員

8.2021-01至今,beat365在線體育官網(wǎng)孟超醫(yī)學(xué)與交叉科學(xué)中心,副研究員


教學(xué)簡(jiǎn)介:

科研簡(jiǎn)介:

主要從事腫瘤精準(zhǔn)免疫與精準(zhǔn)醫(yī)學(xué)診斷方面的基礎(chǔ)與臨床研究,主持國家自然科學(xué)基金青年項(xiàng)目,國家自然科學(xué)區(qū)域創(chuàng)新發(fā)展聯(lián)合基金(聯(lián)合單位主持),福建省自然面上項(xiàng)目等省部廳級(jí)課題13項(xiàng),作為核心成員參與國家科學(xué)儀器研發(fā)重大專項(xiàng)子項(xiàng)目等12項(xiàng)國家和省部級(jí)課題。共發(fā)表SCI論文45篇,以第一作者或通訊作者在Clinical Cancer ResearchIF13.801),Molecular CancerIF44.144),Journal for immunotherapy of cancerIF12.469),Advanced Healthcare Materials (IF: 11.092)等國際高影響力SCI期刊發(fā)表論文18篇(JCR 1區(qū):13篇),相關(guān)研究成果獲得2019年福建科學(xué)技術(shù)進(jìn)步一等獎(jiǎng)等。


社會(huì)兼職:福建省腫瘤藥理專委會(huì)常務(wù)委員,福建省免疫學(xué)會(huì)腫瘤免疫與生物治療專業(yè)委員會(huì)委員,福建省醫(yī)院協(xié)會(huì)醫(yī)學(xué)實(shí)驗(yàn)室分會(huì)常務(wù)委員等學(xué)術(shù)職位。

科研項(xiàng)目:

(1) 國家自然科學(xué)基金委員會(huì), 聯(lián)合基金項(xiàng)目, U22A20328, 脾臟靶向新生抗原疫苗用于肝癌精準(zhǔn)免疫治療

研究, 2023-01-01 2026-12-31, 聯(lián)合單位主持

(2) 國家自然科學(xué)基金委員會(huì), 青年科學(xué)基金項(xiàng)目, 81802413, 環(huán)狀RNA circADAMTS13/miRNA/ADAMTS13信 號(hào)軸在肝癌發(fā)生發(fā)展中的分子機(jī)制研究, 2019-01-01 2021-12-31, 主持

(3) 福建省科技廳, 福建省自然科學(xué)基金面上項(xiàng)目, 2022J011280, CD8組織駐留性T細(xì)胞介導(dǎo)肝癌免疫治療的作用機(jī)制研究, 2022-03 2025-03, 主持

(4) 福建省科技廳, 福建省科技創(chuàng)新聯(lián)合資金項(xiàng)目, 2020Y9044, 基于新生抗原疫苗的精準(zhǔn)免疫療法聯(lián)合PD-1抗體治療肝細(xì)胞癌的分子機(jī)制研究, 2021-08 2024-08, 主持

(5) 福州市科技局, 福州市對(duì)外科技合作項(xiàng)目, 2022-Y-006, 基于新生抗原多肽疫苗的綜合免疫治療體系改善胰腺癌治療療效的作用機(jī)制研究, 2022-06 2024-06, 主持

(6) 福州市科技局, 福州市科技計(jì)劃項(xiàng)目, 2021-S-113, 基于新生抗原的精準(zhǔn)免疫療法對(duì)肝細(xì)胞癌的治療作用機(jī)制研究, 2021-06 2024-06, 主持

(7) 福州市衛(wèi)生健康系統(tǒng), 福州市衛(wèi)生健康系統(tǒng)科技計(jì)劃團(tuán)隊(duì)項(xiàng)目, 2019-S-wt3, 基于無創(chuàng)的循環(huán)腫瘤DNA 液態(tài)活檢技術(shù)實(shí)時(shí)追蹤肝癌克隆結(jié)構(gòu)變化的研究, 2019-06 2022-05, 主持

(8) 福建省科技廳, 福建省自然科學(xué)基金面上項(xiàng)目, 2017J01161, 循環(huán)腫瘤DNA評(píng)估肝癌異質(zhì)性及追蹤腫瘤發(fā)生發(fā)展的研究, 2017-04 2020-04, 主持



已發(fā)表論文:(*為通訊作者)

(1) Chen Hengkai; Li Zhenli; Qiu Liman; Dong Xiuqing; Chen Geng; Shi Yingjun; Cai Linsheng;Liu Wenhan; Ye Honghao; Zhou Yang; Ouyang Jiahe; Cai Zhixiong C ; Liu Xiaolong ; Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infltration in preclinical hepatocellular carcinoma models, Journal for ImmunoTherapy of Cancer, 2022, 10: e004389

(2) Cai Zhixiong C ; Su Xiaoping; Qiu Liman; Li Zhenli; Li Xiaolou; Dong Xiuqing; Wei Fuqun; Zhou Yang; Luo Liuping; Chen Geng; Chen Hengkai; Wang Yingchao; Zeng Yongyi; Liu Xiaolong ; Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion, Molecular cancer, 2021, 2021(20): 164

(3) Cai Zhixiong C ; Zhang Jun; He Yijing; Xia Lin; Dong Xiuqing; Chen Gen; Zhou Yan; Hu Xinlei; Zhong Shen; Wang Yingchao; Chen Hengkai; Xie Dan; Liu Xiaolong; Liu Jingfeng ; Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma, ESMO Open, 2021, 6(1): 100021

(4) Cai Zhixiong C ; Chen Geng; Zeng Yongyi; Dong Xiuqing; Li Zhenli; Huang Yanbing; Xin Fuli;Qiu Liman; Xu Haipo; Zhang Wei; Su Xiaoping; Liu Xiaolong; Liu Jingfeng ; Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma, Clinical Cancer Research, 2019, 25(17): 5284-5294

(5) Cai Zhixiong C ; Xin Fuli; Wei Zuwu; Wu Ming; Lin Xinyi; Du Xiaofan; Chen geng; Zhang Da; Zhang Zhenxi; Liu Xiaolong; Yao Cuiping ; Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal–Organic Framework Nanoparticles to Boost Cancer Immunotherapy, Advanced healthcare materials, 2019, 9(1):1900996

(6) Ying Liu, Bingheng Lu, Zhixiong Cai*, Recent Progress on Mg- and Zn-Based Alloys for Biodegradable Vascular Stent Applications, Journal of nanomaterials, 2019, 2019, 1310792.

(7) Liman Qiu#, Yanbing Huang#, Zhenli Li#, Xiuqing Dong, Geng Chen, Haipo Xu, Yongyi Zeng, Zhixiong Cai*, Xiaolong Liu*, Jingfeng Liu*, Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma, Molecular oncology, 2018,13: 441-455.

(8) Geng Chen #, Zhixiong Cai #, Zhenli. Li, Dong Xiuqing., Xu Haipo., Lin Jianling., Chen Lihong., Huqin Zhang, Xiaolong Liu *, Jingfeng Liu *. Clonal evolution in long-term follow-up patients with hepatocellular carcinoma., International Journal of Cancer, 2018,143: 2862-2870.

(9) Zhenli Li #, Geng Chen #, Zhixiong Cai #, Xiuqing Dong, Liman Qiu, Haipo Xu, Yongyi Zeng, Xiaolong Liu* , Jingfeng Liu*, Genomic and transcriptional Profiling of tumor infiltrated CD8+ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma, OncoImmunology, 2018,8:e1538436.

(10) Xiuqing Dong #, Geng Chen #, Zhixiong Cai #, Zhenli Li, Liman Qiu, Haipo Xu, Yuan Yuan., Xiaolong Liu*, Jingfeng Liu*, CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients., Cell. Physiol. Biochem., 2018, 47: 2602-2612.

(11) Zhixiong Cai#, Geng Chen#, Yongyi Zeng, Xiuqing Dong, Minjie Lin, Xinhui Huang, Da Zhang, Xiaolong Liu*, Jingfeng Liu* , Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma, International Journal of Cancer, 2017,141: 977–985.

(12) Zhixiong Cai#, Da Zhang#, Xinyi Lin, Yunzhu Chen, Ming Wu, Zuwu Wei, Zhenxi Zhang, Xiaolong Liu, Cuiping Yao, Glutathione responsive micelles incorporated with semiconducting polymer dots and doxorubicin for cancer photothermal-chemotherapy, Nanotechnology, 2017, 28: 425102.

(13) Cancan Chen#, Gaoxiong Wang#, Xinhui Huang , Xiuqing Dong, Geng Chen , Mingjie Lin, Zhixiong Cai* and Yongyi Zeng*, Overexpression of galectin-4 promotes cell growth of hepatocellular carcinoma cells in vitro and in vivo, International Journal of Clinical and Experimental Pathology, 2017;10:10233-10242.

(14) Zhixiong Cai, Yongyi Zeng, Bo Xu, Yunzhen Gao, Sen Wang, Jinhua Zeng, Lihong Chen, Aimin Huang, Xiaolong Liu* and Jingfeng Liu*, Galectin-4 serves as a prognostic biomarker for the early recurrence/metastasis of hepatocellular carcinoma, Cancer Science, 2015,105: 1510-1088.

獲獎(jiǎng)情況

先后獲得福建省高層次C類人才(2021年);福建省科學(xué)技術(shù)進(jìn)步一等獎(jiǎng)(2019年,8/10);福建省抗癌協(xié)會(huì)科技進(jìn)步一等獎(jiǎng)(2022年,8/10);中國產(chǎn)學(xué)研合作創(chuàng)新與促進(jìn)優(yōu)秀獎(jiǎng)(2020年,4/10);福州市自然科學(xué)優(yōu)秀學(xué)術(shù)論文二等獎(jiǎng)(2022年),福建省醫(yī)學(xué)會(huì)肝病學(xué)會(huì)優(yōu)秀論文三等獎(jiǎng)(2019年);福州市自然科學(xué)優(yōu)秀學(xué)術(shù)論文三等獎(jiǎng)( 2020年);福州市自然科學(xué)優(yōu)秀學(xué)術(shù)論文二等獎(jiǎng)(2016年),2016、2020年度院先進(jìn)個(gè)人